Table 2.
Tumor response and change in IHC scores (tumor and normal tissue)
| Cat | Dose level (μg/kg) | Treatments | Tumor response | Percent change in tumor LD | Change in tumor IHC score | Change in normal IHC score |
|---|---|---|---|---|---|---|
| 1 | 2 | 5 | PD | +71 | +1 | 0 |
| 2 | 2 | 6 | PD | +81 | NDa | −1 |
| 3 | 2 | 6 | NDb | NDb | −1 | +1 |
| 4 | 2 | 5 | SD | −24 | −1 | +1 |
| 5 | 2 | 5 | SD | +18 | 0 | −1 |
| 6 | 2 | 6 | PD | +32 | NDa | 0 |
| 7 | 20 | 6 | SD | +5 | NDa | 0 |
| 8 | 20 | 6 | PR | −40 | +1 | −1 |
| 9 | 20 | 5 | PD | +12.9c | 0 | −1 |
a
Change in tumor IHC was not determined in three cats because of insufficient pretreatment biopsy samples.
b
Tumor response was not determined in one cat, as the tumor could not be accurately measured to permit RECIST evaluation.
c
Although the change in tumor diameter did not meet criteria for PD, this cat developed a new lesion (metastatic lymph node).
IHC, immunohistochemistry; LD, longest diameter; ND, not determined; PD, progressive disease; PR, partial response; SD, stable disease.